AUSTIN, Texas and WALTHAM, Mass., June 23, 2023 /PRNewswire/ — Aeglea BioTherapeutics, Inc. (“Aeglea”) (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. (“Spyre”), a majority of the independent members of Aeglea’s Board of Directors…